Sanofi (SNYNF) income statement

SNYNFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as SNY

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 17, 2026Score 6/30

$78.48−0.07 (-0.09%)

Close on Oct 19, 2026Market cap $191.40BP/E 22.1Yield –

Sanofi income statement

AnnualQuarterlyTTM

EUR USD

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Cost of Revenue	14,725	14,284	13,656	12,489	14,490	13,853	13,408	13,500	13,096	11,842	12,108
Gross Profit	37,991	33,621	31,350	30,145	31,830	28,722	28,712	28,620	27,751	26,553	26,549
Research & Development	8,849	7,998	7,037	6,833	6,730	6,300	6,738	6,958	6,171	5,723	5,635
Selling, General & Admin	10,769	9,933	9,660	9,186	11,298	10,699	11,063	11,639	11,359	10,488	10,404
Operating Income	7,159	7,845	7,527	10,681	9,608	16,079	3,415	5,520	6,545	7,227	6,236
Interest Expense	635	1,161	1,398	452	435	442	492	514	474	1,023	620
Interest & Investment Income	445	561	632	215	47	60	158	194	166	75	197
Income from Equity Investments	–	–	-124	71	46	409	285	589	96	150	–
Income Tax Expense	1,177	1,302	1,100	2,007	1,842	2,059	135	568	1,942	1,466	786
Income from Continuing Operations	5,616	6,008	5,513	8,496	7,424	14,048	3,230	5,222	4,391	4,964	5,003
Income from Discontinued Operations	3,243	69	366	421	0	0	-113	-15	5,236	347	-138
Net Income incl. Noncontrolling Interests	8,859	6,077	5,879	8,918	7,424	14,048	3,117	5,206	9,628	5,312	4,866
Minority Interest in Earnings	43	63	39	119	66	41	35	123	136	101	112
Net Income	8,816	6,014	5,840	8,799	7,358	14,007	3,082	5,084	9,491	5,211	4,754
Net Income to Common	8,816	6,014	5,840	8,799	7,358	14,007	3,082	5,084	-9,491	-5,211	-4,754
EPS (Basic)(per share)	7.22	4.80	4.66	7.03	5.88	11.19	2.51	4.07	7.56	4.05	3.64
EPS (Diluted)(per share)	7.19	4.79	4.65	7.00	5.85	11.13	2.50	4.05	7.49	4.02	3.60
Shares Outstanding (Basic, Weighted)(shares)	1,220	1,251	1,252	1,252	1,253	1,254	1,250	1,247	1,257	1,287	1,306
Shares Outstanding (Diluted, Weighted)(shares)	1,226	1,256	1,256	1,257	1,257	1,260	1,257	1,255	1,267	1,296	1,321

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 10.5%

Financial strength

Current ratio: 0.99
Debt to equity: 0.31
Debt to assets: 16.8%
Cash to current liabilities: 19.9%

Valuation

P/E ratio: 22.1
Price to sales: –
Price to book: 2.48
Dividend yield: –

See a number that looks wrong?